Sn Genelab Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 08-12-2024
- Paid Up Capital ₹ 0.11 M
as on 08-12-2024
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 08-12-2024
- Revenue 42.68%
(FY 2023)
- Profit 33.02%
(FY 2023)
- Ebitda 46.32%
(FY 2023)
- Net Worth 53.41%
(FY 2023)
- Total Assets 57.95%
(FY 2023)
About Sn Genelab
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹5.00 Cr.
Pratap Mukhopadhyaya, Salil Vaniawala, Jalpaben Vaniawala, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2013PTC077903
- Company No.
077903
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sn Genelab?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pratap Mukhopadhyaya  | Director | 29-Sep-2018 | Current |
| Salil Vaniawala | Director | 16-Dec-2013 | Current |
| Jalpaben Vaniawala | Director | 16-Dec-2013 | Current |
| Shalin Vaniawala | Director | 02-Apr-2022 | Current |
Financial Performance of Sn Genelab.
Sn Genelab Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 42.68% increase. The company also saw a substantial improvement in profitability, with a 33.02% increase in profit. The company's net worth Soared by an impressive increase of 53.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sn Genelab?
In 2023, Sn Genelab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wobble Base Bioresearch Private LimitedActive 11 years 5 monthsPratap Mukhopadhyaya is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 Feb 2022 | ₹5.00 Cr | Open |
How Many Employees Work at Sn Genelab?
Sn Genelab has a workforce of 36 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sn Genelab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sn Genelab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
